HRMY Harmony Biosciences (HRMY) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001802665
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
183
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · $1.9M priced
What the filings say about HRMY
Insiders, 180 days
-$3.1M net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$29.6M
6 notices
Harmony Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Harmony Biosciences Holdings, Inc. insiders sold a net $3.1M of stock across 185 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Sep 17, 2026.
- The trade is 273.4% of the 13,115 shares held after it.
- No other insider sold within 30 days.
- 183 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Budur Kumar sold about $1.5M of HRMY on Sep 18, 2026, the largest insider sale at the company since 2024; 183 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Sep 16, 2026.
- The trade is 6.1% of the 13,115 shares held after it.
- No other insider sold within 30 days.
- 183 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Budur Kumar sold about $34.4K of HRMY on Sep 17, 2026; 183 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Sep 8, 2026.
- The trade is 13.7% of the 13,115 shares held after it.
- No other insider sold within 30 days.
- 183 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Budur Kumar sold about $77.4K of HRMY on Sep 16, 2026; 183 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 4, 2026.
- The trade is 31.9% of the 14,115 shares held after it.
- No other insider sold within 30 days.
- 183 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Budur Kumar sold about $190.1K of HRMY on Sep 8, 2026; 183 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 4, 2026.
- The trade is 7.6% of the 13,115 shares held after it.
- No other insider sold within 30 days.
- 183 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER Budur Kumar sold about $42.8K of HRMY on Sep 8, 2026; 183 funds added in the latest 13F quarter.185 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$3.1M over 180 days
-$3.1M over 90 days
below 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
183 funds bought in last quarter
more than 88% of Pharma & Biotech
Revenue
+21.5% year over year
more than 68% of Pharma & Biotech
Margin
18.3% net margin
more than 87% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.6% of the float short (float per yahoo 2026-10-26) · 5.0 days to cover · settled 2026-09-30
more than 69% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch HRMY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+37.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns HRMY: institutional holders (13F)
13F holdings, latest reported quarter
7,101,965 sh
$258.6M
3,574,115 sh
$130.1M
2,880,489 sh
$104.9M
2,539,512 sh
$92.5M
2,393,588 sh
$87.1M
Congress trades in HRMY
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
HRMY planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
KUMAR BUDUR
Filed 2026-09-18
$1.5M
KUMAR BUDUR
Filed 2026-09-17
$33.8K
KUMAR BUDUR
Filed 2026-09-16
$75.9K
KUMAR BUDUR
Filed 2026-09-08
$1.2M
KUMAR BUDUR
Filed 2026-09-04
$230.2K
HRMY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Pharmaceuticals ETF
$14.5M position · as of 2026-07-31
3.1%
Euclidean Fundamental Value ETF
$2.1M position · as of 2026-06-30
1.6%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$6.7M position · as of 2026-06-30
1.6%
PROFUND VP PHARMACEUTICALS
$174.9K position · as of 2026-06-30
1.5%
Royce Small-Cap Value Fund
$1.6M position · as of 2026-06-30
1.4%
Royce Capital Fund - Small-Cap Portfolio
$2.7M position · as of 2026-06-30
1.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Jeffrey M.Dayno
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.9M
$4.8M
$2.7M
+4%
+20%
2024
$7.1M
$7.7M
$3.3M
-7%
+3%
2022
$514.8K
$2.9M
$748.1K
+49%
+0%
2021
$885.6K
$2.0M
$1.9M
+15%
+13%
2020
$3.2M
$6.4M
$2.7M
-2%
+13%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.1M sold by insiders over 180 days, 183 funds added last quarter, $29.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
HRMY financials
Revenue growth
+21.5%
XBRL, annual
Net margin
18.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$959.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM HRMY
| FY Dec 2025 | $868.5M |
| FY Dec 2024 | $714.7M |
| FY Dec 2023 | $582.0M |
| FY Dec 2022 | $437.9M |
| FY Dec 2021 | $305.4M |
| Jun 2026 | $261.3M |
| Mar 2026 | $215.4M |
| Dec 2025 | $243.8M |
| Sep 2025 | $239.5M |
| Jun 2025 | $200.5M |
| Mar 2025 | $184.7M |
| Dec 2024 | $201.3M |
| Sep 2024 | $186.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+18.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM HRMY
| FY Dec 2025 | +18.3% |
| FY Dec 2024 | +20.4% |
| FY Dec 2023 | +22.1% |
| FY Dec 2022 | +41.4% |
| FY Dec 2021 | +11.3% |
| Jun 2026 | +28.9% |
| Mar 2026 | +15.1% |
| Dec 2025 | +9.2% |
| Sep 2025 | +21.2% |
| Jun 2025 | +19.8% |
| Mar 2025 | +24.7% |
| Dec 2024 | +24.6% |
| Sep 2024 | +24.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$354.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM HRMY
| FY Dec 2025 | $347.9M |
| FY Dec 2024 | $218.7M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $144.3M |
| FY Dec 2021 | $98.3M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $126.0M |
| Sep 2025 | $108.7M |
| Jun 2025 | $79.3M |
| Mar 2025 | $33.9M |
| Dec 2024 | $75.0M |
| Sep 2024 | $70.5M |
At each fiscal year end
Single quarter
Debt to equity
0.15x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity HRMY
| FY Dec 2025 | 0.19x |
| FY Dec 2024 | 0.27x |
| FY Dec 2023 | 0.41x |
| FY Dec 2022 | 0.48x |
| FY Dec 2021 | 1.03x |
| Jun 2026 | 0.15x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.19x |
| Sep 2025 | 0.20x |
| Jun 2025 | 0.22x |
| Mar 2025 | 0.24x |
| Dec 2024 | 0.27x |
| Sep 2024 | 0.31x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
2.31x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt HRMY
| FY Dec 2025 | 2.13x |
| FY Dec 2024 | 1.23x |
| FY Dec 2023 | 1.13x |
| FY Dec 2022 | 0.75x |
| FY Dec 2021 | 0.51x |
| Jun 2026 | 2.31x |
| Mar 2026 | 2.15x |
| Dec 2025 | 2.13x |
| Sep 2025 | 1.77x |
| Jun 2025 | 1.51x |
| Mar 2025 | 1.27x |
| Dec 2024 | 1.23x |
| Sep 2024 | 1.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+20.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity HRMY
| FY Dec 2025 | +20.8% |
| FY Dec 2024 | +25.8% |
| FY Dec 2023 | +29.6% |
| FY Dec 2022 | +61.6% |
| FY Dec 2021 | +24.4% |
| Jun 2026 | +20.5% |
| Mar 2026 | +17.9% |
| Dec 2025 | +20.8% |
| Sep 2025 | +25.9% |
| Jun 2025 | +27.6% |
| Mar 2025 | +24.7% |
| Dec 2024 | +25.8% |
| Sep 2024 | +22.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+14.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets HRMY
| FY Dec 2025 | +14.0% |
| FY Dec 2024 | +16.1% |
| FY Dec 2023 | +17.4% |
| FY Dec 2022 | +32.8% |
| FY Dec 2021 | +8.0% |
| Jun 2026 | +14.6% |
| Mar 2026 | +12.5% |
| Dec 2025 | +14.0% |
| Sep 2025 | +17.4% |
| Jun 2025 | +18.4% |
| Mar 2025 | +16.1% |
| Dec 2024 | +16.1% |
| Sep 2024 | +14.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+35.2%
operating income after a 24.8% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital HRMY
| FY Dec 2025 | +47.2% |
| FY Dec 2024 | +40.2% |
| FY Dec 2023 | +40.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +35.2% |
| Mar 2026 | +32.1% |
| Dec 2025 | +47.2% |
| Sep 2025 | +49.5% |
| Jun 2025 | +45.0% |
| Mar 2025 | +39.5% |
| Dec 2024 | +40.2% |
| Sep 2024 | +33.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+22.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed HRMY
| FY Dec 2025 | +22.6% |
| FY Dec 2024 | +25.9% |
| FY Dec 2023 | +30.9% |
| FY Dec 2022 | +24.7% |
| FY Dec 2021 | +26.0% |
| Jun 2026 | +22.3% |
| Mar 2026 | +19.6% |
| Dec 2025 | +22.6% |
| Sep 2025 | +25.8% |
| Jun 2025 | +27.1% |
| Mar 2025 | +24.8% |
| Dec 2024 | +25.9% |
| Sep 2024 | +24.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
11.69x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing HRMY
| FY Dec 2025 | 13.76x |
| FY Dec 2024 | 13.71x |
| FY Dec 2023 | 15.24x |
| FY Dec 2022 | 18.55x |
| FY Dec 2021 | 73.52x |
| Jun 2026 | 11.78x |
| Mar 2026 | 11.25x |
| Dec 2025 | 13.76x |
| Sep 2025 | 8.67x |
| Jun 2025 | 10.19x |
| Mar 2025 | 12.67x |
| Dec 2024 | 13.71x |
| Sep 2024 | 18.96x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.7B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value HRMY
| FY Dec 2025 | $1.6B |
| FY Dec 2024 | $1.7B |
| FY Dec 2023 | $1.8B |
| FY Dec 2022 | $3.2B |
| FY Dec 2021 | $2.5B |
| Jun 2026 | $1.7B |
| Mar 2026 | $1.2B |
| Dec 2025 | $1.6B |
| Sep 2025 | $1.1B |
| Jun 2025 | $1.4B |
| Mar 2025 | $1.6B |
| Dec 2024 | $1.7B |
| Sep 2024 | $2.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+16.9%
TTM free cash flow over market value at close 2026-10-23
FCF yield HRMY
| FY Dec 2025 | +16.1% |
| FY Dec 2024 | +11.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +4.4% |
| FY Dec 2021 | +3.9% |
| Jun 2026 | +16.8% |
| Mar 2026 | +21.1% |
| Dec 2025 | +16.1% |
| Sep 2025 | +18.7% |
| Jun 2025 | +14.3% |
| Mar 2025 | +11.6% |
| Dec 2024 | +11.1% |
| Sep 2024 | +9.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -0%, PEG needs growth
PEG, trailing HRMY
| FY Dec 2025 | 1.64x |
| FY Dec 2024 | 0.75x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.05x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 1.64x |
| Sep 2025 | 0.17x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.94x |
| Dec 2024 | 0.75x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M |
| EPS (diluted) | 2.71 | 2.51 | 2.13 | 2.97 |
| Operating cash flow | $348.2M | $219.8M | $219.4M | $144.5M |
| Cash | $752.5M | $453.0M | $311.7M | $243.8M |
| Long-term debt | $143.7M | $163.0M | $178.6M | $189.6M |
| Buybacks | n/a | n/a | $100.0M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
HRMY Stock Sonar score 6/7 axes
Find similar shapesCompareHRMY ranks highest on profitability (88th percentile) and institutional and government (88th), and lowest on insider conviction (12th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
HRMY filings, in plain words
Are Harmony Biosciences insiders buying or selling HRMY?
In the 180 days to 2026-10-27, Harmony Biosciences insiders were net sellers, a net $3.1M across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of HRMY?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $29.6M of stock; the latest, by KUMAR BUDUR, was filed 2026-09-18.
Read the full summary
In the 180 days to 2026-10-27, Harmony Biosciences insiders were net sellers of HRMY, a net $3.1M across purchases and sales reported on Form 4 by 1 seller. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $29.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
